China NMPA Inspection - Guiyang Xinlong Shangyitang Traditional Chinese Medicine Hospital - December 04, 2020

The Guizhou Provincial Drug Administration published its 2020 Drug Manufacturing Enterprise Supervision and Inspection Report (Second Issue), covering inspections conducted from July to November 2020. The purpose was to ensure regulatory compliance within drug manufacturing facilities and medical institution preparation rooms throughout Guizhou Province. While the majority of inspected companies, including Guiyang Xinlong Shangyitang Traditional Chinese Medicine Hospital and Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., were found to be compliant, several entities faced significant findings during unannounced inspections.

Specifically, Guizhou Tiandi Pharmaceutical Co., Ltd. (September 2nd) and Guizhou Diyi Health Pharmaceutical Co., Ltd. (September 24th) were cited for Good Manufacturing Practice (GMP) violations. Both companies received orders to rectify their deficiencies within a specified period and were required to suspend production. Guizhou Anshun Xixiu Pharmaceutical Co., Ltd. was also found with a GMP violation on October 13th, resulting in a warning and an interview. Furthermore, Guizhou Yibai Pharmaceutical Co., Ltd. (October 13th) and Guizhou Sanli Pharmaceutical Co., Ltd. (October 21st) were interviewed and mandated to implement rectifications within a defined timeframe, following unannounced inspections organized by the Provincial Bureau. These regulatory actions by the Guizhou Provincial Drug Administration highlight an ongoing commitment to upholding pharmaceutical product quality and safety standards.